Sujata Narayanan
Executive Medical Director, Global Development Lead Pfizer
Seminars
Monday 3rd November 2025
Exploring the Clinical Performance of Disitamab Vedotin-Keytruda Combination in Bladder Cancer
10:30 am
- Building on the past success of ADC-immunotherapy combination therapies
- Contextualizing Disitamab Vedotin-immunotherapy success in bladder cancer
- Outlining additional clinical DV-IO combination response in bladder cancer
